RECRUITING Phase 4 ClinicalTrials.gov

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

Sponsor: Samsung Medical Center • ClinicalTrials.gov ID: NCT07776054

Registry updated: 2026-08-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.

Interventions

SGLT2 inhibitors (Dapagliflozin and Empagliflozin) (Drug)
Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.

Eligibility criteria

Inclusion Criteria: * Age ≥19 years * Persistent atrial fibrillation * H2FPEF score ≥6 or HFA-PEFF score ≥5 * Restoration of sinus rhythm after electrical cardioversion Exclusion Criteria: * Previous use of an SGLT2 inhibitor * Intracardiac thrombus on transesophageal echocardiography * Refusal to participate

Conditions

Atrial Fibrillation SGLT2 Inhibitor DC Cardioversion

Locations

Samsung Medical Center — Seoul, Seoul, South Korea

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment